SANOREX Drug Patent Profile

When do Sanorex patents expire, and when can generic versions of Sanorex launch?

Sanorex is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in SANOREX is mazindol. Additional details are available on the mazindol profile page.

Summary for SANOREX

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	39
Patent Applications:	4,397
DailyMed Link:	SANOREX at DailyMed

US Patents and Regulatory Information for SANOREX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	SANOREX	mazindol	TABLET;ORAL	017247-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Novartis	SANOREX	mazindol	TABLET;ORAL	017247-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for SANOREX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	SANOREX	mazindol	TABLET;ORAL	017247-001	Approved Prior to Jan 1, 1982	3,763,178
Novartis	SANOREX	mazindol	TABLET;ORAL	017247-002	Approved Prior to Jan 1, 1982	3,763,178

International Patents for SANOREX

See the table below for patents covering SANOREX around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	149593
Denmark	149815
Denmark	126114

SANOREX Market Analysis and Financial Projection

Last updated: April 23, 2026

Market dynamics and financial trajectory for SANOREX

SANOREX is not traceable to a specific, clearly identified marketed pharmaceutical product in the public patent, regulatory, or market-access datasets commonly used for financial and competitive trajectory analysis. Without an unambiguous product identity (active ingredient, dosage form, manufacturer/marketing authorization holder, and jurisdictional authorizations), there is no reliable basis to map sales performance, payer dynamics, or patent-driven cash-flow impact.

What is SANOREX in the drug registry sense?

SANOREX is not uniquely identified from the information provided. “SANOREX” could refer to multiple unrelated trade names across countries, and a market/financial trajectory depends on the exact mapping to an active ingredient, formulation, and authorization status.

How do patent and regulatory events drive SANOREX’s market dynamics?

A financial trajectory for a prescription product is typically driven by:

• Patent estate and exclusivity (composition-of-matter, method, formulation, and pediatric/extension terms)
• Regulatory status (approved indication set, label changes, and withdrawals)
• Generic and biosimilar entry path (paragraph IV style challenges where relevant, or local generic pathways)
• Manufacturing and supply constraints (which can dominate revenues even when exclusivity is intact)

No SANOREX-specific patent or exclusivity timeline can be constructed because the product’s active ingredient and jurisdictional authorization are not specified and SANOREX is not uniquely resolvable in standard sources from the prompt alone.

What does the financial trajectory typically look like for a patented drug like SANOREX?

For an identifiable patented small-molecule product, the expected revenue curve follows a recognizable pattern:

1. Launch ramp (pricing and formulary access determine speed)
2. Peak period (label breadth and competitive pressure define durability)
3. Pre-expiry deterioration (managed entry agreements, channel inventory management, and tendering)
4. Post-expiry decline (generic entries and price erosion)
5. Post-loss stabilization (switchers to next-line or lifecycle extensions, if any)

No SANOREX-specific quarterly or annual revenue time series can be produced without an unambiguous product mapping.

What payer and access dynamics matter most for SANOREX?

For high-impact pharma products, payer dynamics usually hinge on:

• Formulary placement tier (preferred vs non-preferred)
• Prior authorization and step edits
• Clinical guideline alignment (which controls utilization)
• Rebates and managed entry terms (driving net price volatility)

No SANOREX-specific payer posture can be derived from the prompt alone because payer policy is jurisdiction- and molecule-dependent.

What competitive forces shape SANOREX pricing and demand?

In real-world product trajectories, demand and price are pressured by:

• Direct competitors in the same mechanism of action class
• Therapeutic substitution (same indication, different pathway)
• Class-wide contracting by large payers
• Multiple generic launches post-exclusivity

SANOREX’s mechanism class and therapeutic indication are not provided, so competitive pressure cannot be grounded in factual category mapping.

Can SANOREX’s financial performance be benchmarked?

Benchmarking requires at least one of:

• Company-reported revenues tied to SANOREX’s active ingredient and market
• Court or regulatory records enabling generic entry timing
• IMS-type or market research identifiers that link SANOREX to a specific label

None of these identifiers exist in the prompt.

What is the patent-driven cash-flow outlook for SANOREX?

Cash-flow outlook depends on:

• Remaining exclusivity horizon
• Probability and timing of generic entry
• Expected net-price trajectory (gross-to-net and tendering)
• Distribution economics (wholesaler inventory cycles)

Without an active ingredient and jurisdictional exclusivity profile, no cash-flow outlook can be stated as fact.

---

Key Takeaways

• SANOREX cannot be connected to a unique active ingredient, authorization, or patent estate from the provided information, so a factual market and financial trajectory cannot be produced.
• Patent, exclusivity, payer access, and competitive entry pathways require unambiguous product identity (active ingredient, dose form, jurisdiction).
• Any attempt to quantify revenues, net price, market share, or cash-flow impact would be non-actionable without a provable mapping to a specific drug.

---

FAQs

1. What data is required to build SANOREX’s financial trajectory?
   A verifiable mapping of SANOREX to an active ingredient, formulation, and jurisdictional marketing authorization, plus its patent and exclusivity timeline.

2. How do patent expiries typically change drug market dynamics?
   They usually trigger generic entry and rapid price erosion, with utilization shifting based on formulary placement and payer contracting.

3. What drives net price more than gross list price?
   Rebates, discounts, tender outcomes, and managed entry agreements.

4. How do label changes affect revenue sustainability?
   New indications and expanded patient eligibility increase addressable demand, while withdrawals and safety limitations reduce it.

5. Why can’t trade name analysis alone predict financial performance?
   Trade names can map to different ingredients and labels across countries, and exclusivity and generic pathways differ by jurisdiction.

---

References

[1] No citable sources are available from the provided prompt to uniquely identify SANOREX as a specific drug product and compile its patent, regulatory, payer, and market performance trajectory.